Pfizer Interest In Biosimilars Appears To Decline As Firm Ceases To Split Out Segment

Launch Of Humira Challenger In 2023 May Rejuvenate The Area

Nov 08 2022

Pfizer's biosimilar business appears to be on the backburner for the time being • Source: Shutterstock